The U.S. Food and Drug Administration has granted approval for ANDA085288, an oral tablet formulation of acetaminophen 300 mg and codeine phosphate 30 mg, marketed by KV PHARM. The product, identified as "ACETAMINOPHEN AND CODEINE PHOSPHATE," was originally submitted on 23 July 1977 and received an approval status (AP). Subsequent labeling submissions were filed on 2 December 1988 (submission 44), 4 May 1988 (submission 43), and 8 October 1996 (submission 11). The tablet is listed as discontinued in the FDA database.
Key details:
- Route: Oral
- Dosage form: Tablet
- Product number: 001
- Marketing status: Discontinued
- Sponsor: KV PHARM
- Application number: ANDA085288
- Active ingredients: Acetaminophen 300 mg; Codeine phosphate 30 mg
Actualizaciones regulatorias30 ago 2026•1 min de lectura
FDA Approves KV PHARM Acetaminophen/Codeine Phosphate Tablet (ANDA085288)
FDA approved KV PHARM's oral tablet containing 300 mg acetaminophen and 30 mg codeine phosphate (ANDA085288). Multiple labeling submissions were filed; the product is now discontinued.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración